Welcome to the InfoSci Platform
Molecular-Docking-Based Anti-Allergic Drug Design

Molecular-Docking-Based Anti-Allergic Drug Design

Anamika Basu, Piyali Basak, Anasua Sarkar
Copyright: © 2017 |Pages: 16
ISBN13: 9781522517627|ISBN10: 1522517626|EISBN13: 9781522517634
DOI: 10.4018/978-1-5225-1762-7.ch027
Cite Chapter Cite Chapter

MLA

Basu, Anamika, et al. "Molecular-Docking-Based Anti-Allergic Drug Design." Pharmaceutical Sciences: Breakthroughs in Research and Practice, edited by Information Resources Management Association, IGI Global, 2017, pp. 711-726. https://doi.org/10.4018/978-1-5225-1762-7.ch027

APA

Basu, A., Basak, P., & Sarkar, A. (2017). Molecular-Docking-Based Anti-Allergic Drug Design. In I. Management Association (Ed.), Pharmaceutical Sciences: Breakthroughs in Research and Practice (pp. 711-726). IGI Global. https://doi.org/10.4018/978-1-5225-1762-7.ch027

Chicago

Basu, Anamika, Piyali Basak, and Anasua Sarkar. "Molecular-Docking-Based Anti-Allergic Drug Design." In Pharmaceutical Sciences: Breakthroughs in Research and Practice, edited by Information Resources Management Association, 711-726. Hershey, PA: IGI Global, 2017. https://doi.org/10.4018/978-1-5225-1762-7.ch027

Export Reference

Mendeley
Favorite

Abstract

Allergens are foreign proteins that when come in contact of part(s) of human body stimulate the production of immunoglobulin types of proteins (antibodies). These allergens react with antibodies (immunoglobulin type E or IgE) produces allergic reactions, also known as immediate-type hypersensitivity reactions. As much as 20% of the general population may be affected by grass pollen as a major cause of allergic disease. EXPB class of proteins are known in the immunological literature as group-1 grass pollen allergens Molecular docking method can be used to identify the predicated the interaction of pollen allergen EXPB1 (Zea m 1), a beta-expansin and group-1 pollen allergen from maize with IgE molecules of human. The World Health Organization recognised allergen immunotherapy, as therapeutics for allergic diseases. RNA Interference (RNAi) is a biological process in which RNA molecules e.g. Small Interfering RNAs (siRNAs) inhibit gene expression, by cleavage and destruction of specific mRNA molecules. Use of Small Interfering RNA (siRNA) is a novel method in the induction of RNA Interference (RNAi), which is a potent method for therapeutics of allergic reactions. Due to various effects of STAT 6 proteins during hypersensitivity reactions caused by pollen allergens, mRNA of STAT6 gene is selected as target gene for allergy therapeutics via Post-Transcriptional Gene Silencing (PTGS). Using molecular docking study a specific sense siRNA is identified as anti allergic drug to treat allergic asthma during immediate type of hypersensitivity reaction, caused by Zea m 1 pollen allergen.

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.